Search the GHTC website

Global health R&D delivers for North Carolina

US government investment in global health R&D has delivered

$2.4 billion
to North Carolina research institutions
35,500+ new jobs
for North Carolina
North Carolina's top USG-funded global health R&D institutions

North Carolina's top USG-funded global health R&D institutions

Duke University
$994.5 million
FHI 360 (previously Family Health International)
$606.2 million
PPD (Pharmaceutical Product Development)
$304 million
University of North Carolina at Chapel Hill (including the Carolina Vaccine Institute)
$288.7 million
Rho Inc.
$45.3 million
RTI International (Research Triangle Institute)
$38.5 million
BioCryst Pharmaceuticals Inc.
$31.3 million
Undisclosed NC-based industry recipients
$27.8 million
Qorvo Inc.
$26.3 million
Mucommune LLC
$8.9 million
North Carolina State University Raleigh
$7.6 million
Advanced Liquid Logic*
$4.6 million
Affinergy LLC
$4.1 million
Redbud Labs Inc.
$4.1 million
Eppin Pharma Inc.
$3.7 million
Wake Forest University
$3.6 million
Attagene Inc.
$3.2 million
$2.8 million
GREER Laboratories (including Allermed Laboratories)
$2.5 million
Medicago USA*
$2.4 million
Global Vaccines Inc.*
$2.2 million
Collaborations Pharmaceuticals Inc.
$2.1 million
Alderon Biosciences Inc.*
$2 million
Atom Bioworks
$1.8 million
NIRvana Sciences Inc.
$1.8 million
Novan Inc.
$1.5 million
Burleson Research Technologies
$1.1 million
Appalachian State University
$997 thousand
East Carolina University
$896 thousand
$810 thousand
University of North Carolina at Greensboro
$748 thousand
Calla Health Foundation
$682 thousand
$663 thousand
Jericho Sciences LLC
$508 thousand
North Carolina Central University
$476 thousand
​Diabetic Health Inc. (formerly Clinical Sensors Inc.)
$371 thousand
Base4 Biotechnology (formerly Nymirum)
$349 thousand
Triangle Biotechnology
$340 thousand
Mycosynthetix Inc.
$325 thousand
AimMax Therapeutics Inc.
$307 thousand
Eldec Pharmaceuticals Inc.
$300 thousand
OncoTrap, Inc.
$299 thousand
Adámas Nanotechnologies
$285 thousand
Indexus Biomedical LLC
$278 thousand
Gradient Medical
$273 thousand
Ribometrix LLC
$268 thousand
Global Bridge Pharmaceutical Inc.
$122 thousand
$92 thousand
Natural Products and Glycotechnology Research Institute*
$75 thousand
SDV Office Systems
$67 thousand

North Carolina's top areas of global health R&D by USG funding

Flioviral diseases (including Ebola, Marburg)
Reproductive health
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Helminth infections (worms & flukes)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Salmonella infections
Snakebite envenoming
Global health R&D at work in North Carolina

RTI International, in partnership with TB Alliance, is supporting the development of new drugs for tuberculosis (TB). RTI helped the alliance bring to market a groundbreaking new drug for highly drug-resistant TB. The drug is part of a combination regimen that has reduced treatment time from up to two years to six months while dramatically improving outcomes. The regimen has a 90 percent treatment success rate, compared to prior treatments that were about 50 percent successful. This lifesaving drug is an important new tool in combatting drug-resistant TB both globally and in the United States.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: Flickr/Victor